BOC-D-3-氟苯丙氨酸 | 114873-11-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: BOC-D-3-氟苯丙氨酸
• 中文别名: Boc-D-3-氟苯丙氨酸；N-Boc-3-氟-D-苯基丙氨酸；N-叔丁氧羰基-D-3-氟苯丙氨酸；N-BOC-3-氟-D-苯基丙氨酸
• 英文名称: boc-L-3-(3-fluorophenyl)alanine
• 英文别名: Boc-3-fluoro-D-phenylalanine；(2R)-3-(3-fluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 114873-11-9
• 化学式: C₁₄H₁₈FNO₄
• 分子量: 283.3
• InChiKey: FPCCREICRYPTTL-LLVKDONJSA-N

物化性质

• 熔点：
  75-79 °C
• 比旋光度：
  -6 º (c=1,MeOH)
• 沸点：
  425.0±40.0 °C(Predicted)
• 密度：
  1.1918 (estimate)
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	(R)-N-BOC-3-Fluorophenylalanine 95% (98% E.E.) Material Safety Data Sheet
Synonym:	N-tert-Butoxycarbonyl-3-Fluorophenyl-D-Alanine
CAS:	114873-11-9

Section 1 - Chemical Product MSDS Name:(R)-N-BOC-3-Fluorophenylalanine 95% (98% E.E.) Material Safety Data Sheet
Synonym:N-tert-Butoxycarbonyl-3-Fluorophenyl-D-Alanine

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
114873-11-9	(R)-N-BOC-3-Fluorophenylalanine	95%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 114873-11-9: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white to off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 75-78 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H18FNO4
Molecular Weight: 283.3

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 114873-11-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(R)-N-BOC-3-Fluorophenylalanine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 114873-11-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 114873-11-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 114873-11-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  BOC-D-3-氟苯丙氨酸 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 以41 mg的产率得到(R)-2-amino-3-(3-fluorophenyl)propanoic acid hydrochloride
  参考文献：
  名称：

  基于手性驱动模式的人法呢基焦磷酸合酶（hFPPS）的基于α-氨基膦酸的变构抑制剂的结合。

  摘要：

  以手性α-氨基膦酸部分为特征的人类法呢基焦磷酸合酶（hFPPS）的基于噻吩并嘧啶的变构抑制剂被合成为对映体富集对，并通过X射线晶体学研究了它们的结合模式。揭示了所有（R）-和（S）-对映异构体的结合方向的普遍共识。这一发现是建立可靠的构效关系模型的先决条件。

  DOI：

  10.1021/acs.jmedchem.9b01104
• 作为产物：
  描述：

  3-氟苯基硼酸 在 4-二甲氨基吡啶 、 chlorobis(ethylene)rhodium(I) dimer 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 、 水 、 异丙醇 为溶剂， 反应 24.5h， 生成 BOC-D-3-氟苯丙氨酸
  参考文献：
  名称：

  基于手性驱动模式的人法呢基焦磷酸合酶（hFPPS）的基于α-氨基膦酸的变构抑制剂的结合。

  摘要：

  以手性α-氨基膦酸部分为特征的人类法呢基焦磷酸合酶（hFPPS）的基于噻吩并嘧啶的变构抑制剂被合成为对映体富集对，并通过X射线晶体学研究了它们的结合模式。揭示了所有（R）-和（S）-对映异构体的结合方向的普遍共识。这一发现是建立可靠的构效关系模型的先决条件。

  DOI：

  10.1021/acs.jmedchem.9b01104

文献信息

• [EN] QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINAZOLINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：FENG YANGBO

  公开号：WO2010056758A1

  公开（公告）日：2010-05-20

  The invention is directed to quinazoline compounds that can inhibit the bioactivity of one or more kinase enzymes, including a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Fit kinase, an Aurora kinase, or a Src kinase, or any combination thereof; to methods of use of those compounds; and to methods of preparation of those compounds. The inventive compounds can be used in the treatment of malconditions including cardiovascular disease, neurogenic pain, hypertension, atherosclerosis, angina, stroke, arterial obstruction, peripheral arterial disease, erectile dysfunction, acute and chronic pain, dementia, Alzheimer's disease, Parkinson's disease, neuronal degeneration, asthma, amyotrophic lateral sclerosis, spinal cord injury, rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, cerebral vasospasm, open angle glaucoma, multiple sclerosis, pulmonary hypertension, acute respiratory distress syndrome, inflammation, diabetes, urinary organ diseases and benign prostatic hypertrophy (BPH), metastasis, cancer, glaucoma, ocular hypertension, retinopathy, autoimmune disease, viral infection, or myocardial pathology.

  这项发明涉及能够抑制一个或多个激酶酶的生物活性的喹唑啉化合物，包括Rho激酶、AKT激酶、p70S6K激酶、LIM激酶、IKK激酶、Fit激酶、Aurora激酶或Src激酶，或其任意组合；这些化合物的使用方法；以及这些化合物的制备方法。这些创新化合物可用于治疗包括心血管疾病、神经性疼痛、高血压、动脉粥样硬化、心绞痛、中风、动脉阻塞、周围动脉疾病、勃起功能障碍、急性和慢性疼痛、痴呆症、阿尔茨海默病、帕金森病、神经元退化、哮喘、肌萎缩侧索硬化、脊髓损伤、类风湿性关节炎、骨关节炎、骨质疏松症、银屑病、脑血管痉挛、开角型青光眼、多发性硬化、肺动脉高压、急性呼吸窘迫综合征、炎症、糖尿病、泌尿器官疾病和良性前列腺增生（BPH）、转移、癌症、青光眼、眼压增高、视网膜病变、自身免疫疾病、病毒感染或心肌病理的恶性疾病的治疗。
• [EN] NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE TOXINE DE CLOSTRIDIUM DIFFICILE
  申请人：VENENUM BIODESIGN LLC

  公开号：WO2017214359A1

  公开（公告）日：2017-12-14

  The present invention relates to benzodiazepine derivative compounds of formula (I), or pharmaceutically acceptable salts thereof. The present benzodiazepine compounds are useful Clostridium difficile inhibitors in the treatment of Clostridium difficile infection in humans. The present invention provides a pharmaceutical composition containing benzodiazepine compounds of formula (I) and a method of making as well as a method of using the same in treating patients infected with Clostridium difficile infection by administering the same. The compounds of the present invention may be used in combination with additional antibiotics or anti-toxin antibody drugs.

  本发明涉及式(I)的苯二氮卓衍生物化合物，或其药学上可接受的盐。目前的苯二氮卓衍生物在治疗人类的克罗斯特氏梭菌感染中是有用的抑制剂。本发明提供了一种含有式(I)的苯二氮卓化合物的药物组合物，以及制备该药物组合物的方法和使用该药物组合物治疗感染克罗斯特氏梭菌的患者的方法。本发明的化合物可以与额外的抗生素或抗毒素抗体药物结合使用。
• Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture
  申请人：Pfizer Inc

  公开号：US20040087797A1

  公开（公告）日：2004-05-06

  This invention relates to dihydro-furan-2-one derivatives, their intermediates and methods of manufacture. As such, the present invention includes methods of making a compound of the formula (V-1) 1 wherein R 2 and P are herein defined. The present invention also relates to the compounds used in such processes.

  本发明涉及二氢呋喃-2-酮衍生物、其中间体及其制备方法。具体而言，本发明包括制备式(V-1)化合物的方法，其中R2和P如本文所定义。本发明还涉及这些过程中使用的化合物。
• [EN] SERINE/THREONINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE SÉRINE/THRÉONINE KINASE
  申请人：GENENTECH INC

  公开号：WO2015085007A1

  公开（公告）日：2015-06-11

  Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

  具有公式I的化合物，在此处定义的R1、X1、X2、X3和X4为ERK激酶的抑制剂。还公开了用于治疗过度增殖性疾病的组合物和方法。
• Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV inhibitors
  作者：Jinyou Xu、Hyun O. Ok、Edward J. Gonzalez、Lawrence F. Colwell、Bahanu Habulihaz、Huaibing He、Barbara Leiting、Kathryn A. Lyons、Frank Marsilio、Reshma A. Patel、Joseph K. Wu、Nancy A. Thornberry、Ann E. Weber、Emma R. Parmee

  DOI：10.1016/j.bmcl.2004.06.099

  日期：2004.9

  equipotent thiazolidide 9. Extensive SAR studies on the phenyl ring of 9 led to the discovery of a novel series of potent and selective DP-IV inhibitors. Introduction of a fluorine at the 2-position proved to be crucial for the potency of this series. The 2,5-difluoro (22q) and 2,4,5-trifluoro (22t) analogues were potent inhibitors of DP-IV (IC(50)=270, 119nM, respectively).

  内部筛选铅β-氨基酰基脯氨酸8的修饰得到了等价的噻唑烷化物9。对9的苯环的广泛SAR研究导致发现了一系列新的有效的和选择性的DP-IV抑制剂。事实证明，在2位上引入氟对于该系列的效能至关重要。2,5-二氟（22q）和2,4,5-三氟（22t）类似物是DP-IV的有效抑制剂（分别为IC（50）= 270、119nM）。